Skip to main content

Topic

Biologics

72 published works

  1. Drug & Device Law

    Frozen Assets — E.D. Pa. Refuses to Let a Qui Tam Relator Turn a Shipping Glitch into a Fraud Verdict

    By Michelle Yeary

    We have all had the experience of ordering something online, watching the delivery truck icon crawl across the map for three days, and then opening the box to find everything…

  2. Big Molecule Watch

    FDA Issues Its First Freeze-Dried Plasma License

    By Lianne Frydendal

    On July 29, 2026, the FDA announced that it had licensed EZPLAZ FDP, the first freeze-dried (lyophilized) plasma product to be licensed in the United States. The license was issued…

  3. Big Molecule Watch

    Year in Review: Top Legal Developments of 2025

    By Tara Thigpen|Riley Wyberg|Sam Herron

    This past year contained a number of significant developments in litigation involving biologics and biosimilars.  The following is a recap of the top three legal developments that we covered on…

  4. Global Policy Watch

    European Biotech Act: Potential new extension for supplementary protection certificates (SPCs) for ATMPs and biotechnology medicines

    By Grant Castle, Inga-Marlene Pietsch

    This is one in a series of Inside EU Life Sciences blogs on the European Commission’s (“Commission’s”) latest proposal for a European Biotech Act. On 16 December 2025, the Commission…

  5. Big Molecule Watch

    FDA Approves Lupin’s Pegfilgrastim Biosimilar, ARMLUPEG

    By Timothy Beavers

    Lupin Limited announced on December 1 that it received FDA approval for its biosimilar product, ARMLUPEG (pegfilgrastim-unne).  ARMLUPEG is approved as a 6 mg/0.6 mL single-dose prefilled syringe presentation, referencing…

  6. Big Molecule Watch

    Register Today: Webinar Series: How the BPCIA Is Reshaping Biologics and Biosimilar Patenting Strategies

    By Sarah Clarke

    Join Michael Siekman, Allegra Padula, and Riley Wyberg as they open our webinar series with “The BPCIA Has Changed How Companies Should Be Protecting Innovative Biologics and Biosimilars—Has Your Company…

  7. Big Molecule Watch

    Recent Biologics Decisions at Health Canada

    By Timothy Beavers

    In the last few weeks, Health Canada issued several decisions concerning biologics. On October 17, Health Canada approved, via a Notice of Compliance, Biocon Biologics Ltd.’s YESINTEK (ustekinumab injection) and…

  8. Big Molecule Watch

    Aflibercept BPCIA Multi-District Litigation Updates

    By Gabriella Montes

    The aflibercept multi-district litigation consists of multiple actions consolidated in the Northern District of West Virginia, with Regeneron Pharmaceuticals, Inc. (“Regeneron”) filing suit under the Biologics Price Competition and Innovation…

  9. Big Molecule Watch

    HyClone Seeks to Quash Amgen’s Subpoena Issued in Amgen/Accord Denosumab BPCIA Litigation

    By Allegra Padula

    On May 14, 2025, HyClone Laboratories, LLC (“HyClone”) filed a Motion to Quash in the U.S. District Court for the District of Utah, seeking to quash Amgen Inc.’s (“Amgen”) subpoena…

  10. Big Molecule Watch

    Year in Review: Top Legal Developments of 2024

    By Timothy Beavers|Kevin DeJong|Alexandra Lu|Joshua Weinger

    As 2024 has come and passed, we saw another year of significant developments in litigation involving biologics and biosimilars.  The following is a recap of the top four legal developments…